Summary
The platinum analogues JM8 and JM9 were assigned randomly to 16 patients with pleural mesothelioma. Nine patients received JM8 and seven received JM9. Two of nine (22%) JM8-treated patients had objective responses (confidence limits 2.8%–60.0%, 95% confidence level). JM9 was more emetogenic than JM8, but not to a significant level. However, patients who received JM9 significantly preferred this drug to be given on an inpatient basis, in contrast with patients receiving JM8, who received the majority of courses as outpatients.
Primary cytotoxic drug resistance is a major obstacle to successful treatment of mesothelioma, and phase II studies of novel agents should continue in an effort to circumvent this problem.
This is a preview of subscription content, log in via an institution to check access.
References
Aisner J, Wiernik PH (1981) Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8 335
Cantwell BMJ, Earnshaw M, Harris AL (1986) Phase II study of a novel antifolate N10-propargyl-5, 8 dideazafolic acid (CB3717) in malignant mesothelioma. Cancer Treat Rep (in press)
Falkson G, Vorobiof DA, Lerner HJ (1983) A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother Pharmacol 11 94
Harvey VJ, Slevin ML, Ponder BAJ, Blackshaw AJ, Wrigley PFM (1984) Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and Adriamycin. Cancer 54 961
Lee FH, Canetta R, Issell BF, Lenaz L (1983) New platinum complexes in clinical trials. Cancer Treat Rev 10 39
Lerner HJ, Schoenfeld DA, Martin A, Falkson G, Borden E (1983) Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52 1981
Mbidde EK, Smith IE, Harland S (1986) Phase II trial of carboplatin (JM8) in the treatment of patients with mesothelioma (M). Br J Cancer 54 215
Mintzer D, Kelsen D, Frimmer D, Heelan R, Gralla R and Ochoa M (1984) Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Proc Am Soc Clin Oncol abstract C-1012
Sørensen PG, Bach F, Bork E, hansen HH (1985) Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69 1431
World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva (WHO offset publication 48)
Zidar B, Pugh R, Schiffer L, Raju R, Vaidya K, Horne D, Baker L (1983) Treatment of six cases of mesothelioma with doxorubicin and cis-platinum. Proc Am Soc Clinic Oncol abstract C-880
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cantwell, B.M.J., Franks, C.R. & Harris, A.L. A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 18, 286–288 (1986). https://doi.org/10.1007/BF00273405
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00273405